Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044525
Status:
COMPLETED
Last Update Posted:
2014-12-23
First Post:
2002-08-30
Brief Title:
Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY59-8862 in Patients With Taxane-Resistant Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Breast cancer is the most common form of cancer among women in developing countries accounting for approximately one-fifth of all female cancers in the United States Although mortality rates are declining in some countries it remains the leading cause of death in women aged 40-55 years The median survival for women with metastatic breast cancer is 2-3 years but there is significant variability in this population The primary goals of treatment in patients with metastatic breast cancer are improvement or maintenance of quality of life and prolongation of survival The taxanes paclitaxel and docetaxel were incorporated into the treatment of metastatic breast cancer in the 1990s The usefulness of the taxanes is limited by the development of tumor resistance to these agents This phase II trial with BAY59-8862 will be conducted to determine the anti-tumor efficacy of BAY59-8862 in taxane-resistant metastatic breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None